A clinical study of Miransertib (ARQ-092) in patients with Proteus syndrome

Trial Profile

A clinical study of Miransertib (ARQ-092) in patients with Proteus syndrome

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Miransertib (Primary)
  • Indications Proteus syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 09 Apr 2018 New trial record
    • 03 Apr 2018 According to an Arqule Form 10-K, March 2018, the company plans to initiate with the NIH a registrational program with miransertib in patients with Proteus Syndrome in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top